Vistagen Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
VTGN$0.18-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-inCapital · TreasuryStock · AccumulatedOther Comprehensive Income · AccumulatedDeficit · TotalStockholders’Equity | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||
| Balance at March 31, 2025 | 29,001,481 | $29 | $481,956 | $(3,968) | $5 | $(407,632) | $70,390 |
| Stock-based compensation expense | — | — | 916 | — | — | — | 916 |
| Sale of common stock pursuant to 2019 Employee Stock Purchase Plan | 95,037 | — | 161 | — | — | — | 161 |
| Issuance of common stock under Open Market Sale Agreement, net of issuance costs | 190,067 | — | 397 | — | — | — | 397 |
| Unrealized loss on marketable securities available-for-sale, net | — | — | — | — | (4) | — | (4) |
| Net loss | — | — | — | — | — | (15,095) | (15,095) |
| Balance at June 30, 2025 | 29,286,585 | $29 | $483,430 | $(3,968) | $1 | $(422,727) | $56,765 |
| Common Stock · Additional Paid-in Capital · Treasury Stock · Accumulated Other Comprehensive Income · Accumulated Deficit · Total Stockholders' Equity | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||||||
| Balance at March 31, 2026 | 39,624,839 | $40 | $516,767 | $(3,968) | $(2) | $(477,317) | $35,520 | ||||||||
| Stock-based compensation expense | — | — | 991 | — | — | — | 991 | ||||||||
| Sale of common stock pursuant to 2019 Employee Stock Purchase Plan | 387,798 | — | 74 | — | — | — | 74 | ||||||||
| Unrealized loss on marketable securities available-for-sale, net | — | — | — | — | (5) | — | (5) | ||||||||
| Issuance of common stock under Open Market Sale Agreement, net of issuance costs | 1,580,176 | 1 | 927 | — | — | — | 928 | ||||||||
| Issuance of common stock upon exercise of Pre-Funded Warrants | 2,788,620 | 3 | — | — | — | — | 3 | ||||||||
| Net loss | — | — | — | — | — | (13,030) | (13,030) | ||||||||
| Balance at June 30, 2026 | 44,381,433 | $44 | $518,759 | $(3,968) | $(7) | $(490,347) | $24,481 | ||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.